Meet Sencyr
Presenting to you LiveSkin Probiotics™, the world's first-ever technology working with your skin for long-lasting results.
Behind our discovery
Restoring balance in the skin microbiome
The bacterial community composition on the skin is tightly connected to the overall health of the human body. As such, imbalances within our skin microbiome can contribute to a wide variety of conditions such as acne, eczema, and rosacea.
Targeted modulation of the human microbiome offers the potential for revolutionary therapy. Inspired by the powerful influence of microbial modulation, S-Biomedic has made the skin the focus of its microbiome research.
Our technology
LiveSkin Probiotics™ to address skin conditions
Our products directly modulate the skin microbiome; enabling the recovery of a healthy microbiome community and opens the door to effectively treat acne and other skin diseases.
Our partners
Developed with the support of:
The project Skin Microbiome has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 890930.
The S-Biomedic is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
Since its inception in 2001, DSM Venturing, the outside-in arm of our open innovation approach, has invested in more than fifty emerging innovative companies in the US, Europe and Israel.
Beiersdorf AG is a cosmetics company headquartered in Hamburg, Germany. Its flagship brand NIVEA is one of the world's largest skin care brands.
With over 70 investments, Verve Ventures is one of Switzerland's most active early-stage investors and offers private and institutional investors direct and professional access to startup investments.
Flanders Innovation & Entrepreneurship support innovation and entrepreneurship, and contribute to a favourable business climate in Flanders.
CG Health Ventures as a strategic partner supports S-Biomedic with capital, connections and advice.
Flanders Investment & Trade (FIT) is the point of contact for international business in Flanders. They facilitate investment projects in Flanders and give support to Flemish export companies.
“We modulate the population of skin bacteria so that the skin can return to its natural and healthy state.”
— Bernhard Paetzold PhD, Chief Scientific Officer and Co-founder of S-Biomedic
Meet our team
Veronika Oudova
Chief Executive Officer & Co-founder
Bernhard Paetzold
Chief Scientific Officer & Co-founder
Marc Guëll
Scientific Director & Co-founder
Wesley Carpentier
Chief Commercial Officer
Get in touch
If you’d like to hear more about what we do at S-Biomedic, or have a question for our team, drop us a line and we would love to get in touch with you.